Filing Flows › Evofem Biosciences (EVFM) › Q1 2026 › vs Q1 2025
Evofem Biosciences (EVFM) Q1 2026 vs Q1 2025 (year over year)
Evofem Biosciences's revenue rose $54K (+6%) from $845K in Q1 2025 to $899K in Q1 2026.
Evofem Biosciences, Q1 2026: revenue $899K (+6% year over year), operating margin -508.2%, net loss $5.5M, operating cash flow $2.3M. The chart draws each line against Q1 2025, the increases inside each band.
Every line
| Line | Q1 2026 | Q1 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $899K | $845K | $54K | +6% |
| Income tax benefit | $1K | $0 | $1K | — |
| Net loss | $5.5M | −$956K | $6.4M | — |
| Costs & expenses | $6.4M | $1.5M | $4.9M | +332% |
| Operating costs | $5.5M | $518K | $5.0M | +956% |
| Interest & other, net | $897K | −$629K | $1.5M | — |
| Operating cash sources | $7.8M | −$396K | $8.2M | — |
| Depreciation & amortization | $79K | $229K | −$150K | -66% |
| Share-based compensation | $15K | $70K | −$55K | -79% |
| Working capital & other | $7.7M | −$695K | $8.4M | — |
| Net loss absorbed | $5.5M | −$956K | $6.4M | — |
| Operating cash flow | $2.3M | $560K | $1.7M | +311% |
Questions
How much did Evofem Biosciences's revenue grow year over year in Q1 2026?
Evofem Biosciences's revenue rose $54K (+6%) from $845K in Q1 2025 to $899K in Q1 2026.